# US 2022/0031652 A1 · Use of an organometallic compound as a dna-demethylating agent

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0031652 A1
- Document ID: US20220031652A1
- Status: Published application
- Kind: A1
- Application number: 17/292,689
- Filed: 2019-11-12
- Published: 2022-02-03
- Earliest claimed: 2018-11-12
- Assignees: Universite De Lorraine; Institut National De La Sante Et De La Recherche Medicale (Inserm)
- Applicants: Universite De Lorraine; Institut National De La Santé Et De La Recherche MéDicale - Inserm
- Inventors: Stéphanie GRANDEMANGE; Antonio MONARI; Philippe GROS; Pierre François CARTRON
- Web page: https://patentgrep.com/patent/US20220031652A1

## CPC

- A61K 31/295: Iron group metal compounds
- A61P 35/00: Antineoplastic agents
- A61K 8/19: containing inorganic ingredients
- A61K 8/4926: {having six membered rings}
- A61P 35/02: specific for leukemia
- A61Q 19/00: Preparations for care of the skin
- A61Q 19/06: for countering cellulitis
- C12Q 1/6806: Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay (C12Q1/6804 takes precedence)
- A61K 2800/58: Metal complex; Coordination compounds
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61Q: SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

Disclosed is the non-therapeutic use, as a DNA-demethylating agent, of at least one organometallic compound including an iron atom bound to two terpyridine groups. Further disclosed are method related to applying such agent as medicine.

## Claims

### Claim 1

A method for performing DNA demethylation for non-therapeutic purposes, comprising administering a DNA-demethylating agent to a subject, the agent comprising of at least one organometallic compound comprising an iron atom bound to two terpyridine groups of following general formula (I):
wherein:
R1 to R6, identical or different are chosen from among: a hydrogen atom; a linear or branched alkyl chain of formula CnH2n+1 with n=1 to 12; a COOH group; an SO3H group; a PO3H group; an aromatic cycle of formula (II) to (VI) below:
where
Y are each independently from the others, a CH group or a nitrogen atom;
R7 is chosen from among an OCYH2Y+1 group with y=1 to 10; SCwH2w+1 with w=1 to 10; N(CmH2m+1)2 with m=1 to 6, COOH; SO3H or PO2H3;
Z designates an oxygen atom, a sulphur atom or an NH group;
the dotted line represents a C—C bond at the level of the connection point of the aromatic cycle of formula (II) to (VI) to the terpyridine groups of the organometallic compound of formula (I);
X− is a counterion.

### Claim 2 (depends on 1)

The method of claim 1, wherein R1 to R6 correspond to a hydrogen atom.

### Claim 3 (depends on 1)

The method of claim 1, wherein R1, R3, R4, 66 are identical and correspond to a hydrogen atom, and R2 and R5 are identical and designate a benzene of following formula (VII):

### Claim 4 (depends on 1)

The method of claim 1, wherein R1, R3, R4, 66 are identical and correspond to a hydrogen atom, and R2 and R5 are identical and designate a pyridine radical of following formula (VIII):
where the dotted line represents a C—C bond between the carbon carried by the pyridine radical and the carbon carried by the terpyridine group of the organometallic compound of formula (I).

### Claim 5 (depends on 1)

The method of claim 1, wherein the counterion X− is chosen from among: Cl−, Br− ou I−.

### Claim 6 (depends on 1)

The method of claim 1, wherein said organometallic compound is capable of leading to a direct DNA demethylation.

### Claim 7

A medicine comprising an organometallic compound comprising an iron atom bound to two terpyridine groups, having a general formula (I):
wherein:
R1 to R6, identical or different are chosen from among: a hydrogen atom; a linear or branched alkyl chain of formula CnH2n+1 with n=1 to 12; a COOH group; an SO3H group; a PO3H group; an aromatic cycle of formula (II) to (VI) below:
where
Y are each independently from the others, a CH group or a nitrogen atom;
R7 is chosen from among an OCYH2Y+1 group with y=1 to 10; SCwH2w+1 with w=1 to 10; N(CmH2m+1)2 with m=1 to 6, COOH; SO3H or PO2H3;
Z designates an oxygen atom, a sulphur atom or an NH group;
the dotted line represents a C—C bond at the level of the connection point of the aromatic cycle of formula (II) to (VI) to the terpyridine groups of the organometallic compound of formula (I);
X− is a counterion.

### Claim 8 (depends on 7)

A method for treatment of diseases linked to a cell hyperproliferation, comprising administering an effective amount of the medicine of claim 7 to a subject in need thereof.

### Claim 9 (depends on 7)

A method for treatment of cancers, comprising administering an effective amount of the medicine of claim 7 to a subject in need thereof.

### Claim 10 (depends on 7)

A method for treatment of glioblastomas, promyelocytic leukaemia, prostate, ovarian, lung, breast, digestive tract cancers, pancreatic, head and neck, colon cancers, non-Hodgkin's lymphomas or melanomas, comprising administering an effective amount of the medicine of claim 7 to a subject in need thereof.

### Claim 11 (depends on 7)

A method for treatment of tumours resistant to cisplatin, 5-fluorouracile, tamoxifen or also doxorubicin or to other anticancer compounds, comprising administering an effective amount of the medicine of claim 7 to a subject in need thereof.

### Claim 12 (depends on 7)

A method for treatment of inflammation, obesity, neurodegenerative diseases or cardiovascular diseases, comprising administering an effective amount of the medicine of claim 7 to a subject in need thereof.

### Claim 13 (depends on 2)

The method of claim 2, wherein the counterion X− is chosen from among: Cl−, Br− ou I−.

### Claim 14 (depends on 3)

The method of claim 3, wherein the counterion X− is chosen from among: Cl−, Br− ou I−.

### Claim 15 (depends on 4)

The method of claim 4, wherein the counterion X− is chosen from among: Cl−, Br− ou I−.

### Claim 16 (depends on 2)

The method of claim 2, wherein said organometallic compound is capable of leading to a direct DNA demethylation.

### Claim 17 (depends on 3)

The method of claim 3, wherein said organometallic compound is capable of leading to a direct DNA demethylation.

### Claim 18 (depends on 4)

The method of claim 4, wherein said organometallic compound is capable of leading to a direct DNA demethylation.

### Claim 19 (depends on 5)

The method of claim 5, wherein said organometallic compound is capable of leading to a direct DNA demethylation.

### Claim 20 (depends on 7)

The medicine of claim 7, wherein R1 to R6 correspond to a hydrogen atom.
